Supira Medical

Congratulations Dr. Karim Al-Azizi, MD, FACC, FSCAI, FESC, Erika Ortiz, Ishika Parupudi, Osniel Gonzalez Ramos, Shelby McCoy, Selena Ortega, MS, CCRC, Eddie Hernandez, B.S., MPH, Christopher Quiocho, and Andrés Miramontes - being the first in TX is an incredible accomplishment!

The SUPPORT II train continues to move across the U.S., this time arriving at UC Davis Health; congratulations and much appreciation to Dr. Garrett Wong and Dr. Tai Pham! The Supira System features a custom, low-profile 10Fr introducer and provides up to 5.5 liters per minute of continuous flow while using dual sensors to provide real-time aortic and ventricular pressures. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world. https://lnkd.in/g4ryacNc

It is our absolute pleasure to work with innovative cath labs across the United States, including CentraCare in St. Cloud, MN. who is leading the way in the Midwest. Congratulations and much appreciation to Drs. Stephen Kidd, Thom Dahle, MD, FACC, FSCAI, Brian Stegman and the esteemed research team including Shontal Goss and Erica Reberg. The Supira System features a custom, low-profile 10Fr introducer and provides up to 5.5 liters per minute of continuous flow while using dual sensors to provide real-time aortic and ventricular pressures. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.

Bonjour, and thanks for joining us at PCR! We had an amazing week meeting with physicians, collaborators, and colleagues to discuss how our next-generation system will transform the pVAD space. The Supira System is designed to reduce risks, expand access to care, and support ease of use in high-risk PCI and cardiogenic shock. It features a custom, low-profile 10Fr introducer and provides up to 5.5 liters per minute of continuous flow while using dual sensors to provide real-time aortic and ventricular pressures. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.

Huge thanks to Dr. Azeem Latib and the entire PCR leadership team for hosting such a thoughtful and engaging Innovator’s Day. We were honored to have our CEO, Nitin Salunke, invited to participate in the Innovator’s Exchange Hub panel discussion. He joined an exceptional group of leaders, including Prof. Dr. Alexandre Abizaid, Sanjeev Bhatt, Eric Le Royer, Nikolai "Nik" Nikitin, MD, PhD, and Radoslaw Parma, who are focused on shaping the future of cardiovascular care. The value of bringing together clinicians, innovators, and industry in an open forum accelerates shared learnings and strengthens global partnerships.

What a strong start to the SUPPORT II Pivotal Study with multiple sites initiating their subject enrollment in the first week: Montefiore Health System, Hillcrest HealthCare System (Oklahoma Heart Institute), and UC Davis Health. This significant milestone was the result of hard work and collaboration with site principal investigators Andrea Mignatti, Kamran Muhammad MD FACC FSCAI, Garrett Wong, and Tai Pham along with key advisors Azeem Latib and Gagan Singh. The SUPPORT II Pivotal Study for HRPCI is led by national co-PI’s David Kandzari and Ajay Kirtane. The Supira System features a custom, low-profile 10Fr introducer and provides up to 5.5 liters per minute of continuous flow while using dual sensors to provide real-time aortic and ventricular pressures. The Supira System is an investigational device and is not approved for sale in the U.S. or anywhere in the world.

Quite an honor for our CEO, Nitin Salunke, to be invited as a panelist during the upcoming Innovator's Exchange Hub at PCR during Innovator's Day. We'd love for you to join and learn more - see you in Paris! 📅 Monday, May 18th | 🕒 13:45-14:45 📍 Room 342AB, Palais des congrès, Paris

Today, cardiologists still must choose between access or flow; and that needs to change. A new study of our breakthrough pVAD in Circulation: Cardiovascular Interventions adds to the growing evidence showing successful use of a low-profile, high-flow pVAD in high-risk PCI. At Supira Medical, we’re focused on developing a versatile platform that will transform the pVAD space; a next-generation device that enables interventionalists and heart failure specialists to do more, treat more, and make support easier to use. LEARN MORE HERE➥; https://lnkd.in/gNAPzxAu The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S.

Multiple milestones. Clear direction. • FDA approval to start the SUPPORT II pivotal trial in high-risk PCI • Percutaneous axillary access for Cardiogenic Shock • Welcoming D. Keith Grossman to the board These milestones demonstrate strong momentum and reflect our focus on expanding options to support patients when they need it the most. LEARN MORE HERE➥https://lnkd.in/gbM9XxsP The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S.

It’s been an inspiring week for Supira Medical as our next-generation pVAD continues to generate strong interest across the cardiovascular community. Our Supira System was featured during multiple podium presentations at #THT, #HoustonShock, and #CRT where leading interventional cardiologists and heart failure specialists focused on innovative solutions that advance care for patients facing complex coronary disease and cardiogenic shock. We are deeply grateful to the faculty and investigators who continue to partner with us in advancing a new approach to support patients when they need it most. And as our clinical journey continues to build momentum, we’re excited to share that another important milestone is just around the corner. Stay tuned! The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. #pVAD #innovation #medtech #makingadifference